In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Viatris Inc.

Generics And Biosimilars Industry Reshaped By Transformations

The latest Generics Bulletin Top 50 ranking of global generics and biosimilars companies sees a new name in the top five amid transformations for some of the leading off-patent players. Meanwhile, a number of mid-level firms shift position and newcomers climb into the bottom of the table.

Outlook 2023 Generic Drugs

Humira Biosimilars Prepare For US Competition In 2023

The advent of biosimilar competition to Humira in the US in 2023 represents the largest loss-of-exclusivity opportunity ever for the off-patent industry. But with a host of biosimilar sponsors awaiting launches throughout the year, it remains to be seen how competition will play out.

Outlook 2023 United States

US FDA’s Non-Cancer Accelerated Approval Drugs Get Their Own Public Databases

Accelerated Approval Program web page links to searchable databases for accelerated approvals of infectious disease products, vaccines, and other nonmalignant indications. New databases, which include products that converted to regular approval or were withdrawn, are modeled after Oncology Center of Excellence’s cancer drug databases that debuted in 2021.

Review Pathway Post Market Regulation & Studies

Zydus Sees Revlimid Generic Revenues Beyond Q4 As It Waits For Antitrust Suit To Play Out

Zydus, along with Bristol Myers Squibb and generics companies like Mylan, Cipla and Dr. Reddy’s, has been named in an antitrust suit involving BMS’ blockbuster drug Revlimid. For now, it expects revenues from the generic to stretch beyond Q4 FY’23. Meanwhile, a recent acquisition of Watson, which made APIs for the Teva group, should shore up declining API revenues

Commercial Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Generic Drugs
    • Drug Delivery
      • Transdermal
  • Other Names / Subsidiaries
    • Acton Pharmaceuticals, Inc.
    • Agila, Bioniche Pharma Holdings Limited
    • Alaven Pharmaceutical, LLC
    • Antula Healthcare AB
    • Bertek
    • Dow B. Hickham
    • Dow Hickam Pharmaceuticals, Inc.
    • Generics (UK) Ltd.
    • Jai Pharma
    • Madaus Pharma
    • Meda AB
    • Meda Pharmaceuticals Inc.
    • Mylan Inc.
    • Mylan Laboratories Limited (formerly Matrix Laboratories Limited)
    • Mylan Specialty (formerly Dey Pharma L.P.)
    • Rottapharm Madaus
    • Mylan Technologies, Inc.
    • UDL Laboratories
    • Viatris Inc.
UsernamePublicRestriction

Register